API | vilaprisan

vilaprisan Report issue

Small molecule Experimental

AACT DrugBank PubChem

Active Ingredient History

NOW

Vilaprisan is a synthetic and steroidal selective progesterone receptor modulator (SPRM) which is under development by Bayer HealthCare Pharmaceuticals for the treatment of endometriosis and uterine fibroids. It is a potent and highly selective partial agonist of the progesterone receptor (PR). As of 2017, the drug is in phase II clinical trials for the aforementioned indications. ^Wikipedia

Chemistry

SMILES: C[C@]12C[C@H](c3ccc(S(C)(=O)=O)cc3)C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C(F)(F)C(F)(F)F
InChIKey: JUFWQQVHQFDUOD-ANRPBIDPSA-N
Mol. Mass: 544.58
ALogP: 5.92 Partition coefficient
ChEMBL Molecule:
vilaprisan

More Chemistry

Pharmacology

Mechanism of Action:
- Progesterone receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

bay1002670 | vilaprisan

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Clinical Trial, Phase I (Phase 1)

Endometriosis (Phase 2)

Leiomyoma (Phase 3)

Uterine Diseases (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 17
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue